AD/PD 2021 | Barriers to major advances in the Alzheimer’s field

Stephen Salloway • 10 Mar 2021

AD/PD 2021

Despite being on the verge of meaningful breakthroughs in Alzheimer’s disease (AD) research, many challenges remain in reaching clinical advancements in diagnosis, treatment, and prevention. Stephen Salloway, MD, MS, Butler Hospital and Brown University, Providence, RI, shares his thoughts on some of the greatest needs in AD in order to continue advancing the field. Making AD a public health priority in the aging population, sharing research data and building on current progress are all essential to move forward. This interview took place during the AD/PD™ 2021 conference.

Disclosures

Dr. Salloway reports grants, personal fees and non-financial support from Biogen, grants and personal fees from Eisai, grants, personal free and non-financial support from Avid, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Lilly, personal fees from Genentech, personal fees and non-financial support from Roche, outside the submitted work.